Sertraline-Associated Tremor
Sertraline (Zoloft) can cause tremor, which is listed as an adverse reaction in Zoloft prescribing information. [1] Drug-induced tremor is most often managed by reducing the dose or stopping the offending medication when the tremor is clinically significant. [2]
Incidence and Clinical Presentation
Tremor is reported as a treatment-emergent adverse reaction in pooled placebo-controlled trials of sertraline. [1] Sertraline can also be associated with other movement-related adverse effects such as akathisia and “jitteriness/anxiety syndrome,” which can present with prominent restlessness and distress. [1,3]
Risk Factors and Diagnostic Considerations
Tremor severity and timing relative to sertraline initiation or dose changes should be assessed to support medication causality. [2,3] Other serotonin- or medication-related movement syndromes should be considered clinically when additional symptoms are present, since tremor is part of a broader spectrum of drug-induced movement disorders. [4]
Management Approach
Tremor management begins with clinical assessment of severity and functional impact. [2] Medication change is recommended when tremor is bothersome or function-limiting, with management options including dose reduction or discontinuation of sertraline. [2] In suspected antidepressant-induced “activation” or jitteriness syndromes, discontinuation has been associated with prompt symptom improvement in case experience. [3]
Differentiation From Akathisia-Related Activation
Akathisia is characterized by subjective distressing restlessness and an inability to sit or stand still. [5] If sertraline-induced akathisia is identified, management options include dose reduction or discontinuation, with addition of propranolol described as a treatment option in reviews of drug-induced extrapyramidal effects. [5,6]
Safety Monitoring During Changes
Discontinuation or dose reduction of antidepressants can be associated with neuromuscular symptoms including tremor and akathisia as part of antidepressant withdrawal syndromes. [7] Tremor and related activation symptoms should therefore be monitored after any sertraline dose change to distinguish ongoing drug adverse effects from withdrawal phenomena. [7]
When Escalation of Care Is Needed
Immediate clinical evaluation is warranted when tremor is severe, rapidly progressive, or accompanied by other concerning neurologic or systemic symptoms, since drug-induced movement disorders can include syndromes requiring urgent management. [4] Clinical evaluation is also warranted when medication-induced movement symptoms raise safety concerns, because medication adverse effects may necessitate rapid adjustment of therapy. [4,7]